Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...

U.S. Market Expected to Grow from USD 0.81 Billion to USD 3.31 Billion by 2035; Europe Market Forecast to Reach USD 2.18 Billion as Advanced Therapy Research Expands.Austin, United States, June 09, ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

AAVone ® 2.1 has achieved ~1x10 16 genome copies (GC)/L of cell culture and greater than 70% full capsids at harvest, representing a significant advance over AAVone ® 1.0 and conventional ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes ...

Adeno-associated virus (AAV) is the most popular vector of choice for gene therapy because of its low immunogenicity and ability to infect numerous cells and tissue types. However, with hundreds of ...

Virica Biotech ("Virica"), a cell enhancer company specializing in Viral Sensitizers (VSE ™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the ...

ROCKVILLE, Md., May 8, 2026 /PRNewswire/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® single-plasmid AAV production ...